Canada· CA-DIN-02296314

ELAPRASE

A idursulfase product containing idursulfase, registered in Canada by TAKEDA CANADA INC. The same ATC class is registered in 14 of our 19 countries.

ATC A16AB09

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedELAPRASEATCA16AB09REGISTER NO.CA-DIN-02296314PACKS LISTED0CHECKEDOctober 1, 2026

Where it is registered

Idursulfase is registered in 14 of 19 countries.

Countries holding a registration under ATC A16AB09 (idursulfase), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 9 of them publish a price we can compare per daily dose

Idursulfase · ATC A16AB09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
IDURSULFASE
Manufacturer
TAKEDA CANADA INC
Country
Canada (CA)
ATC code
A16AB09
ATC class
Idursulfase
Defined daily dose
5 mg, P
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9d66368e-20c0-4832-8c2e-258a3605772c
GET /v1/drugs/9d66368e-20c0-4832-8c2e-258a3605772c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02296314",
  "form": "SOLUTION",
  "class": "Human",
  "routes": [
    "INTRAVENOUS"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "A16AB09",
  "schedule": [
    "Prescription",
    "Schedule D"
  ],
  "drug_code": "78165",
  "strengths": [
    "2 MG"
  ],
  "ahfs_class": null,
  "substances": [
    "IDURSULFASE"
  ],
  "product_categorization": null
}

See everything about idursulfase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.